Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 685 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CROHN'S DISEASE Clear all
Active, not recruiting No phase listed Observational

Response Assessment in SB CD

NCT03646708
View directory record Official record
Conditions
Small Bowel Crohn's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 7, 2026, 1:05 AM EDT
Recruiting No phase listed Observational

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

NCT04846959
View directory record Official record
Conditions
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment
Interventions
Risankizumab, Comparator
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Female only
Enrollment
818 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
2
States / cities
Morrisville, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 7, 2026, 1:05 AM EDT
Completed No phase listed Observational

OPERA Database - Crohn's Protocol

NCT01720368
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 7, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

NCT02513459
View directory record Official record
Conditions
Crohn Disease
Interventions
Risankizumab 600 mg IV, Risankizumab 180 mg SC
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chevy Chase, Maryland • Chesterfield, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 7, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

NCT00101946
View directory record Official record
Conditions
Crohn's Disease
Interventions
683699
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Garden Grove, California • Roseville, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 7, 2026, 1:05 AM EDT
Terminated Phase 4 Interventional Results available

Cimzia Versus Mesalamine for Crohn's Recurrence

NCT01696942
View directory record Official record
Conditions
Crohn's Disease
Interventions
Cimzia, Mesalamine
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 7, 2026, 1:05 AM EDT
Active, not recruiting Phase 3 Interventional

A Long-term Extension Study of Ustekinumab in Pediatric Participants

NCT05092269
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 7, 2026, 1:05 AM EDT
Recruiting Phase 3 Interventional

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931
View directory record Official record
Conditions
Crohn's Disease
Interventions
Duvakitug, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years to 80 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
125
States / cities
Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 7, 2026, 1:05 AM EDT
Withdrawn Phase 2 Interventional

Vedolizumab Post Op Study

NCT02834754
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab, placebo
Drug
Lead sponsor
Marc Schwartz
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 7, 2026, 1:05 AM EDT
Completed No phase listed Observational

Exacerbating Factors in Inflammatory Bowel Disease

NCT01405105
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Not listed
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 7, 2026, 1:05 AM EDT
Completed Not applicable Interventional

Effect of Grapes in Inflammatory Bowel Disease

NCT05972694
View directory record Official record
Conditions
Crohn Disease
Interventions
Freeze dried grape powder
Dietary Supplement
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 7, 2026, 1:05 AM EDT
Not listed Not applicable Interventional

Diet as Essential Therapy (DIET) for Inflammatory Bowel Disease

NCT03012542
View directory record Official record
Conditions
Crohn Disease
Interventions
Diet 1, Diet 2
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 7, 2026, 1:05 AM EDT
Terminated Phase 3 Interventional Results available

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

NCT01316939
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Little Rock, Arizona • Tucson, Arizona • La Jolla, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 7, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease

NCT00267722
View directory record Official record
Conditions
Crohn's Disease
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 7, 2026, 1:05 AM EDT
Terminated Phase 4 Interventional Results available

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

NCT04626947
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
Interventions
Bezlotoxumab
Biological
Lead sponsor
David Binion, MD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 7, 2026, 1:05 AM EDT
Completed Phase 4 Interventional Results available

Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)

NCT03723447
View directory record Official record
Conditions
Pain, Postoperative, Crohn Disease, Inflammatory Bowel Diseases, Colorectal Cancer, Gastrointestinal Cancer, Gastrointestinal Disease, Digestive System Disease, Pain, Pain, Neuropathic, Intestinal Disease
Interventions
Liposomal bupivacaine, Bupivacaine/epinephrine/dexamethasone
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 7, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

NCT03395184
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-06651600 Placebo, PF-06651600, Placebo PF-06700841, PF-06700841
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
57
States / cities
Dothan, Alabama • Beverly Hills, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 7, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

NCT01393899
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
41
States / cities
Anaheim, California • Cypress, California • Oceanside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 7, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease

NCT01442363
View directory record Official record
Conditions
Perianal Crohn's Disease
Interventions
BLI-1300 low dose, BLI-1300 high dose, placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
17
States / cities
Anaheim, California • San Francisco, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 7, 2026, 1:05 AM EDT
Completed Not applicable Interventional

Patient Automated Text Hovering for IBD

NCT04388865
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Control, Text-based Clinical Hovering
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 7, 2026, 1:05 AM EDT
Terminated No phase listed Observational

Systems Biology of Gastrointestinal and Related Diseases

NCT05579444
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 7, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease

NCT00267709
View directory record Official record
Conditions
Crohn's Disease
Interventions
Visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 7, 2026, 1:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluate Established Anti-DEFA5 mAbs Diagnostic Efficacy and Safety in IBD

NCT05663671
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Colitis, Indeterminate Colitis
Interventions
Diagnostic Test
Diagnostic Test
Lead sponsor
Meharry Medical College
Other
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 7, 2026, 1:05 AM EDT
Completed Phase 2 Interventional

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

NCT00055523
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab (D2E7)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
43
States / cities
Berkeley, California • Long Beach, California • San Diego, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Oct 7, 2026, 1:05 AM EDT